Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Organisation › Details

T3 Pharmaceuticals AG

T3 Pharma was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The Company is focusing on immuno-oncology (bacteria-based) therapies for the treatment of solid tumors. Cancer immunotherapy is seen as a turning point in the fight against cancer. Unlike traditional therapies that attack the tumor directly, the goal of immunotherapies is to stimulate the immune system to selectively recognize and attack tumor cells. T3 is among the first companies supported by BaseLaunch. It was awarded «Science Startup of the year 2018» at Falling Walls Venture, won the business plan competition in 2016 and recently the W.A. de Vigier Award. *


Period Start 2015-05-01 established (s-offc
  Predecessor University of Basel
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 bacterial treatment (bacteria as »drug«)
Persons Person Ittig, Simon Josef (T3 Pharmaceuticals 201909 CEO + Co-Founder)
  Person 2 Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
Region Region Basel BS
  Country Switzerland
  Street 50/70 Klingelbergstr.
c/o Biozentrum, Universität Basel
  City 4056 Basel
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: T3 Pharmaceuticals AG. (9/26/19). "Press Release: Closing of Financing Round and Strengthening of Development Team Paves the Way for T3 Pharma to Enter the Clinic".
Record changed: 2020-10-22


Picture [iito] Plain Stupid Simple 650x80px

More documents for T3 Pharmaceuticals AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top